1	Evaluation of serological tests for detecting SARS-CoV-2 antibodies: implementation in
2	assessing post vaccination status
3	Running title: Evaluation of serological tests for detecting SARS-CoV-2 antibodies
4	Authors' details
5	1.Dr. Sally A. Mahmoud (Corresponding author)
6	Biogenix Lab G42, Abu Dhabi, UAE
7	Email ID: <u>sally.abdulla@g42.ai</u>
8	2.Dr. Subhashini Ganesan
9	G42 Healthcare, UAE
10	Email ID: <u>Subhashini.g@g42.ai</u>
11	3.Mr. Shivaraj Naik
12	Biogenix Lab G42, Abu Dhabi, UAE
13	Email ID : <u>shivaraj.Naik@g42.ai</u>
14	4 Ms. Safaa Bissar
15	Biogenix Lab G42, Abu Dhabi, UAE
16	Email ID: <u>Safaa.Bissar@g42.ai</u>
17	5.Ms. Isra Zamil
18	Biogenix Lab G42, Abu Dhabi, UAE
19	Email ID: <u>Isra.Zamil@g42.ai</u>
20	6.Dr.Walid Abbas Zaher
21	G42 Healthcare, UAE
22	Email ID : <u>Walid.Zaher@g42.ai</u>

23

24

G42-Public

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 Abstract

26 Background

The anti-SARS-CoV-2 immunological assays have promising applications in the control and surveillance of the current COVID-19 pandemic. Therefore, large number of serological assays are developed in the commercial market to measure SARS-CoV-2 antibodies, which requires evaluation before their application in large scale.

31 **Objectives**

To evaluate the performances of commercially available serological assays for detecting
SARS-CoV-2 antibodies.

34 Methods

35 The study compared the performances of six different methods for detection of antibodies 36 against SARS-CoV-2 which includes (i) Genscript SARS-CoV-2 surrogate virus 37 neutralization test kit [Test A] (ii) Diasorin - SARS-CoV-2 S1/S2 IgG detection [Test B] (iii) 38 Alinity SARS-CoV-2 IgG II [Test C] (iv) Diasorin – SARS-CoV-2 TrimericS IgG [Test D] 39 (v) Roche Elecsys Anti-SARS-CoV-2 – cobas [Test E] (vi) AESKULISA (AESKU Enzyme Linked Immunosorbent Assay) [Test F] against the gold standard Plaque Reduction 40 41 Neutralization Test (PRNT). 42 **Results**

Test E had the highest sensitivity and Test A had the highest specificity The ROC for tests A,
C, D and E showed optimum cut-offs that differed from the manufacturer's recommendation.
Test D had the best performance considering all the performance indicators with the highest
agreement with the PRNT results. Parallel testing of test A with test D and test B had the
optimum performance.

48 Conclusion

49 Serological assays that are commercially available are very promising and show good 50 agreement with the standard PRNT results. Studies on large samples for optimization of the 51 assay cut-off values and cost-effective evaluations on parallel testing methods are needed to 52 make recommendations on these commercial assays.

53 **Importance**

54 Serological assays that are commercially available are very promising and this paper adds 55 new knowledge about the optimization of these kits for evaluating post vaccination antibodies status. It highlights the positive and negative aspects of each of these assays in terms of 56 57 sensitivity, specificity, positive and negative predictive values, and the agreement of results 58 with the standard neutralization test. When serological assays are being used to assess post-59 vaccine immune status, a balance of all parameters needs to be considered rather than 60 emphasizing only on high specificity. This is particularly relevant in the current situation 61 where vaccination is happening around the globe, high sensitivity assays will result in 62 reporting a lower percentage of false negative reports and avoids panic about lack of vaccine response. It is important that we understand the strengths and limitations of commercially 63 64 available serological assays for better application of these tests to understand immune 65 response and the duration of protection post vaccination.

66 Key words: SARS-CoV-2; Serological assays; COVID-19; ELISA; CLIA

67 Background

The emergence of this global pandemic of COVID-19 has created an increased need for large scale PCR testing and serological assays. Serological testing has enormous applications in handling the current pandemic, it has both individual and population level practical applications that can facilitate pandemic response. At the individual level it can help G42-Public

72 differentiate recent and past infections of COVID-19, immune status post-vaccination to 73 study the need for booster doses and identifying vaccine intervals. At the population level it helps study the epidemiology of SARS-CoV-2 pandemic, seroprevalence, and thereby help 74 75 public health experts make recommendations on travel, social distancing, and the protective 76 status of the population. [1] There are several serodiagnosis assay platforms that are being 77 used for COVID-19 infections: the FDA has issued emergency authorization for ELISA, lateral flow immunoassay, and microsphere immunoassay. [2] These tests measure the 78 79 antibody to nucleocapsid N protein antigens and antibodies binding to SARS-CoV-2 spike protein S, but not all spike-binding antibodies are functional or blocks viral infection, hence 80 81 they do not indicate the functional measure of the antibody that inhibits SARS-CoV-2 82 infection. Ideally, tests should measure the neutralizing antibodies, which implicate 83 protection from infection. The gold standard for measuring neutralizing antibodies is the 84 plaque reduction neutralization test (PRNT). PRNT is however not practical for large scale as 85 it requires skilled manpower, high-level biohazard security (BSL-3 level) and requires long 86 turnaround time of five days. [3,4]

Therefore, to address this gap, a lot of commercial serological assays are developed and are now available in the market. A meta-analysis done on these serological assays for detecting antibodies against SARS-CoV-2 have shown that assays using the S antigen and testing IgG antibodies perform with better sensitivity than N antigen and Ig M based tests. [5]

It is important that we understand the strengths and limitations of commercially available serological assays for better application for these tests to understand immune response and the protection and duration of protection after vaccination. Hence this research tries to evaluate the various methods for detecting SARS-CoV-2 antibodies compared to the gold standard PRNT.

G42-Public

96 **Objective**

97 To evaluate the performances of commercially available serological assays for detecting
98 SARS-CoV-2 antibodies

99 Methods

The study compared six different methods for detection of antibodies against SARS-CoV-2
detection post vaccination for COVID-19 against the gold standard Plaque Reduction
Neutralization Test (PRNT). The six different methods are (i) Genscript SARS-CoV-2
surrogate virus neutralization test kit [Test A] (ii) Diasorin - SARS-CoV-2 S1/S2 IgG
detection [Test B] (iii) Alinity SARS-CoV-2 IgG II [Test C] (iv) Diasorin – SARS-CoV-2
TrimericS IgG [Test D] (v) Roche Elecsys Anti-SARS-CoV-2 – cobas [Test E] (vi)
AESKULISA (AESKU Enzyme Linked Immunosorbent Assay) [Test F]

107 The PRNT is a serological test which utilizes the ability of a specific antibody to neutralize a 108 virus, in turn, preventing the virus from causing the formation of plaques in a cell monolayer. 109 In this study, Vero E6 cells were grown to a confluent monolayer in a 6 well plate. The 110 positive control was (Pooled Serum sample of Vaccinated and/or Covid-19 positive patient) 111 and viral stock diluted in Dulbecco's modification of Eagle medium (DMEM) was used as 112 negative control.

Interpretation is based on 50% neutralization, which is the last dilution of serum capable of inhibiting 50% of the total plaques (virions). Negative control should have plaque count \geq 50%, positive control should be plaque count \leq 50% of negative control, and titer at which 50% reduction of plaques is there in comparison to the negative control is taken as the antibody titer. For positive PRNT results, the cut off for positive is 1:20 dilution.

118 The study was done on 125 samples, of which 69 stored de-identified excess serum samples 119 collected from post-vaccination patients who requested post-vaccination antibody testing for

antibody levels against SARS-CoV -2 Virus and 56 negative serum samples from nonvaccinated COVID-19 negative patients. Each individual sample was tested using the PRNT
method and with all the six different serological assays, and the results of each method were
compared to the gold standard reference method which is PRNT.

124 All serological assays were done based on manufacturers' guidelines and recommendations.

Table 1 shows the details of the various serological assays evaluated in this study. Test A and F were enzyme linked immunosorbent assay (ELISA) based tests, tests B,D and E were

127 chemiluminescent immunoassay (CLIA) based tests and test D was based on128 chemiluminescent microparticle immunoassay (CMIA)

129 **Results**

130 125 samples were used in this study and PRNT was done on all 125 samples. Due to a lack of 131 sufficient sample volume, some of the serological assays were not performed for certain 132 samples. The borderline/equivocal results that were above the cut-off values for positive 133 reports were considered positive. Table 2 shows the number of samples tested using each 134 assay and the results of each.

Test E had the highest sensitivity followed by test C and F. Test A had the highest specificity
followed by test B and D. Test E though had the highest sensitivity had the lowest specificity
compared to the other rapid tests as shown in Table 3.

When the high sensitivity tests E and C were followed by serial testing with tests A and B
with high specificity, it improved specificity of the tests E and C with a lower sensitivity.
[Figure 1] and [Figure 2]

Also employing two tests with high specificity in parallel for example test A with test B or test D, improved the sensitivity to 92% and 95% respectively, with only a slight loss in specificity. [Table 4]

144	When a functional test like test A is combined with a quantitative test in parallel and serial
145	testing, it shows that test A in parallel testing with test B or test D has the optimum sensitivity
146	and specificity. (Table 4 and Table 5) Test A in serial testing with test B shows the maximum
147	specificity. (Table 5)
148	ROC curve was plotted for all the serological assays and the area under the curve was largest
149	for test D followed by test A and test B, showing the best performance to differentiate
150	positive and negative results compared to the PRNT results. (Figure 3 and Table 6)
151	Based on the ROC optimum cutoffs for the tests were estimated and these were similar to the
152	manufacturer's values for tests B and F. However, tests A, C, D and E showed different cut
153	offs based on our ROC curves than the one recommended by the manufacturers. From the
154	adapted ROC cut offs sensitivity, specificity, and overall agreement with the PRNT results
155	were calculated. [Table 7]

For test A, the manufacturers had an initial cut-off of 20% inhibition, which was changed due to the FDA recommendations to 30% to increase specificity. However, comparing test A results with the PRNT reports, showed 20% as optimum cut-off. The scatter plot of the distribution of % inhibition of test A based on the PRNT reports show the number of positive cases missed, with the increase in cut-off values by 10%. [Figure 4]

161 Test A showed higher sensitivity and overall agreement with PRNT when 20% inhibition was

- used as a cut-off then the recommended 30%. [Figure 5]
- 163

164 Discussion

165 This study compared six immunoassays for detection of IgG antibodies against SARS-CoV-2

against the standard viral neutralization test PRNT.

G42-Public

In this study, tests A and B had the lowest sensitivity but had a high specificity and PPV. But studies that evaluated test A had demonstrated test A to have high sensitivity [6,7]. However, this might be because all these studies used cutoff as 20% inhibition, which was later changed according to FDA recommendation to 30%. [8] A study that compared test A to PRNT similar to our study used 30% as cutoff and showed that sensitivity ranged from 77% - 100% and specificity was 95% - 100% [9], which was similar to our study results when 30% cutoff was used.

The ROC curve adapted cutoff for test A was around 20% inhibition and when 20% was used as a cutoff for test A the sensitivity increased to 92.31% and the overall agreement with the PRNT results was better (90.4%) suggesting 20% inhibition as a more optimum cut off for the test.

Another study that evaluated test A suggested that the test might require specific cutoffs with respect to ethnic, geographical background and the prevalence of COVID-19 infections. The study also showed that introduction of an equivocal range with repeat testing within the range of 18 - 22% can reduce the false positive results.[10]

Based on the ROC threshold values, tests D and E did not correlate with the manufacturers cut-off. Raising the cut-offs for tests D and E as per the ROC values showed increased specificity and agreement with the PRNT results without much change in sensitivity. However, for test C raising the cut-off increased specificity with a huge drop in sensitivity, but the agreement with the PRNT results were better.

Studies suggest revision of cut- off values provided by manufacturers, as most of the assay validation are done on a small sample size and among specific ethnic or regional group.[11] Therefore more evaluation studies and optimum cut-offs need to be defined before these serological assays are used in large scale to evaluate vaccination status of the population.

G42-Public

191 Test E had the highest sensitivity in this study as reported in similar studies, but these studies 192 have also reported high specificity, which our study did not find. [12,13] 193 The sensitivity of test B was similar to that reported in other studies [12]. Studies evaluating 194 C and E demonstrated higher specificity of test C and test E compared to our study. [14] A 195 meta-analysis on antibody tests for SARS-CoV-2 showed that tests using ELISA and CLIA-196 based methods performed better [5]. In our study test A and F are based on ELISA and tests 197 B, D and E were CLIA-based tests. While tests D, E and F showed higher sensitivities, the 198 sensitivities of test A and B were low. 199 Test C was evaluated by a study which compared antibodies in post-vaccination patients 200 compared with pre-pandemic serum samples and claims high sensitivity and a specificity of 201 100%. While our study showed that the sensitivity of test C was high, the specificity was low

202 compared to this study. [15] This might be because these studies have not compared the203 assays with the PRNT method, but with the RT-PCR assay validation.

Test D had good sensitivity and specificity with the highest agreement with the PRNT results,as also supported by another that evaluated test D. [16]

In addition, when a functional test like test A was tested with quantitative tests in parallel, it is observed that the overall sensitivity increases. An optimum sensitivity and specificity are achieved when test A is done in parallel with test B. This kind of combination of two antibody tests are being studied and it shows that it increases the ability to capture the positive results. [17]

The CDC recommends serological tests with high sensitivity and specificity and tests detecting IgG or both IgG and IgM. This is because currently serological tests are recommended by CDC only for identifying persons with previous infections or to identify resolving infections and for better understanding the epidemiology of SARS-CoV-2. [18]

G42-Public

However, these antibody tests help us understand the development of immune response and the longevity of the antibodies developed post-vaccination for COVID-19. This surveillance becomes essential to identify vaccine efficiency and make recommendation on booster doses and the intervals for vaccination.

The WHO, in collaboration with Coalition for Epidemic Preparedness Innovations (CEPI), and the National Institute for Biological Standards and Control (NIBSC), has come up with the International standards for anti-SARS-CoV-2 immunoglobulins. This is very crucial for a standard comparison as vaccine developers have been using various immunoassays with different measuring units making the comparison of immunogenicity difficult. Hence with these recommendations future studies can make the comparison of immunogenicity more standardized and will be less challenging. [19]

226 Most COVID-19 vaccinations use the S protein or S-domains as immunogen target. [20] 227 Therefore these serological assays that target antibodies against S protein and the RBD 228 directed IgG detection serve as a good candidate for evaluating vaccine response. Therefore, 229 keeping this in mind, when serological assays are being used to assess post-vaccine immune 230 status, a balance of all parameters needs to be considered rather than emphasizing more on 231 only high specificity. This is particularly relevant in the current situation where vaccination is 232 happening around the globe and the percentage of vaccination is increasing, high sensitivity 233 assays will result in reporting a lower percentage of false negative reports. This will help 234 assess the immune status and avoids panic about lack of vaccine response. Thus, 235 recommendations based on a balance of all these parameters are needed.

236 Strengths

237 Most evaluation studies compare the serological assays with RT-PCR reports. This study is238 one of its kind that compares commercial serological assays using the same serum sample

G42-Public

and by evaluating the results with the gold standard PRNT reports. Thus, this study reducesthe biases and provides a standard comparison.

241 Limitations

The number of samples were limited and additional parameters like days post vaccination and the type of vaccine were not taken into consideration in this study, which could have provided further insights on the serological assay performances.

245 Conclusion

246 Serological assays that are commercially available are very promising and show good 247 agreement with the standard PRNT results. We recommend further studies of these 248 serological assays with large number of samples, to understand more about the performance 249 of these assays. Moreover, performing two tests in parallel testing improves the sensitivity 250 and a better alternative to conventional PRNT, however cost-effective evaluations are needed 251 to recommend these. We suggest optimization of the cut offs values for these serological 252 assays considering the prevalence, ethnic and geographical variations. Recommendations 253 based on the balance of all performance indicators rather than just specificity will help in the 254 application of these serological assays in assessing post-vaccination status.

255 Funding statement

The study was not funded by any funding body, it was done in Biogenix lab as a part of research.

258 Ethics approval and consent to participate.

259 The Ethics approval was obtained from Department of Health (DOH) Institutional review

260 board (IRB), Abu Dhabi. All methods were carried out in accordance with relevant guidelines

and regulations.

262 Informed consent statement

- 263 Informed consent was waived off by the Department of Health (DOH) Institutional review
- 264 board (IRB), Abu Dhabi.

265 Data Availability

- 266 The data is available with the corresponding author, Dr. Sally, Director of Biogenix G42 lab
- and will be produced on request.

268 Conflict of interest

The authors declare that they have no conflict of interest regarding the publication of thispaper.

271 **References**

1. Bryant JE, Azman AS, Ferrari MJ, Arnold BF, Boni MF, Boum Y, Hayford K,

273 Luquero FJ, Mina MJ, Rodriguez-Barraquer I, Wu JT. Serology for SARS-CoV-2:

- apprehensions, opportunities, and the path forward. Science Immunology. 2020 May
 19;5(47).
- Amanat F, Stadlbauer D, Strohmeier S, Nguyen TH, Chromikova V, McMahon M, et
 al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nature
 medicine. 2020 Jul;26(7):1033-6.
- Perera, R.A., Mok, C.K., Tsang, O.T., Lv, H., Ko, R.L., Wu, N.C., Yuan, M., Leung,
 W.S., Chan, J.M., Chik, T.S. and Choi, C.Y., 2020. Serological assays for severe
 acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March
 2020. Eurosurveillance, 25(16), p.2000421.

G42-Public

283 4. Okba NM, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM
--

- Severe acute respiratory syndrome coronavirus 2-specific antibody responses in
 coronavirus disease 2019 patients. Emerg. Infect. Diseases. 2020;26(7).
- 5. Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG. Antibody Tests in
 Detecting SARS-CoV-2 Infection: A Meta-Analysis. *Diagnostics*. 2020; 10(5):319.
- Putcharoen O, Wacharapluesadee S, Chia WN, Paitoonpong L, Tan CW,
 Suwanpimolkul G, et al. Early detection of neutralizing antibodies against SARS CoV-2 in COVID-19 patients in Thailand. PloS one. 2021 Feb 12;16(2):e0246864
- 291 7. Müller K, Girl P, von Buttlar H, Dobler G, Wölfel R. Comparison of two commercial
- surrogate ELISAs to detect a neutralising antibody response to SARS-CoV-2. Journal
 of Virological Methods. 2021 Mar 8:114122
- Food and Drug Administration (FDA). USA. cPass[™] SARS-CoV-2 Neutralization
 Antibody Detection Kit. Available at: <u>https://www.fda.gov/media/143583/download</u>.
 (Accessed on 3/3/2021)
- Papenburg J, Cheng MP, Corsini R, Caya C, Mendoza EJ, Manguiat KJ, et al.
 Evaluation of a Commercial Culture-free Neutralization Antibody Detection Kit for
 Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison with an
 Anti-RBD ELISA Assay. medRxiv. 2021 Jan 1.
- 301 10. Bond K, Nicholson S, Lim SM, Karapanagiotidis T, Williams E, Johnson D, Hoang
 302 T, Sia C, Purcell D, Mordant F, Lewin SR. Evaluation of serological tests for SARS-
- CoV-2: Implications for serology testing in a low-prevalence setting. The Journal of
 infectious diseases. 2020 Oct 15;222(8):1280-8.
- 305 11. Marzia N, Massimo P, Sandro G, Ciotti M, Miano R, Massimo A, Bernardini S.
 306 SARS-CoV-2 infection serology: a useful tool to overcome lockdown?. Cell Death
 307 Discovery. 2020;6(1).

G42-Public

308	12. Manthei DM, Whalen JF, Schroeder LF, Sinay AM, Li SH, Valdez R, Giacherio DA,
309	Gherasim C. Differences in performance characteristics among four high-throughput
310	assays for the detection of antibodies against SARS-CoV-2 using a common set of
311	patient samples. American journal of clinical pathology. 2021 Feb;155(2):267-79.
312	13. Wakita M, Idei M, Saito K, Horiuchi Y, Yamatani K, Ishikawa S, Yamamoto T,
313	Igawa G, Hinata M, Kadota K, Kurosawa T. Comparison of the clinical performance
314	and usefulness of five SARS-CoV-2 antibody tests. Plos one. 2021 Feb
315	8;16(2):e0246536.
316	14. Ainsworth M, Andersson M, Auckland K, Baillie JK, Barnes E, Beer S, Beveridge A,
317	Bibi S, Blackwell L, Borak M, Bown A. Performance characteristics of five
318	immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. The Lancet
319	Infectious Diseases. 2020 Dec 1;20(12):1390-400.
320	15. Narasimhan M, Mahimainathan L, Raj E, Clark AE, Markantonis J, Green A, et al.
321	Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative
322	IgG and IgM assays in infected, recovered, and vaccinated groups. medRxiv. 2021
323	Jan 1.
324	16. Bonelli F, Blocki FA, Bunnell T, Chu E, De La O A, Grenache DG, et al. Evaluation
325	of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of
326	circulating antibodies. Clin Chem Lab Med. 2021 Mar 12. doi: 10.1515/cclm-2021-
327	0023. Epub ahead of print. PMID: 33711225.
328	17. Schnurra C, Reiners N, Biemann R, Kaiser T, Trawinski H, Jassoy C. Comparison of
329	the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based
330	antibody tests. J Clin Virol. 2020 Aug;129:104544. doi: 10.1016/j.jcv.2020.104544.
331	Epub 2020 Jul 6. PMID: 32663788; PMCID: PMC7836838.

G42-Public

332	18. Center for Disease Control and Prevention (CDC). COVID-19. Interim guidelines for
333	COVID-19 antibody testing. Available at: <u>https://www.cdc.gov/coronavirus/2019-</u>
334	ncov/lab/resources/antibody-tests-guidelines.html (Accessed on 3/3/2021)
335	19. Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, Plotkin S,
336	Knezevic I. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. The
337	Lancet. 2021 Mar 23.
338	20. Lee N, McGeer A. The starting line for COVID-19 vaccine development. The Lancet.
339	2020 Jun 13;395(10240):1815-6.

340

Table 1: Details of the six commercial serological assays 341

Test	Reagent/kit	Method	Manufacturer	Isotype	Target	Run time
					protein	(minutes)
А	cPass SARS-COV-2	ELISA	Genscript	IgG	RBD	180
	surrogate virus				unit of	
	neutralization test kit				S 1	
В	Diasorin SARS-CoV-2	CLIA	Diasorin	IgG	S1/S2	35
	S1/S2 IgG detection					
С	Alinity SARS-CoV-2 IgG	CMIA	Abbott	IgG	RBD	20
	П				unit of	
					S 1	
D	SARS-CoV-2 TrimericS	CLIA	Diasorin	IgG	RBD	20
	IgG				unit of	
					S 1	
Е	Elecsys Anti-SARS-CoV-2	CLIA	Roche	IgG &	RBD	20
	– cobas			IgM	unit of	
					S 1	
F	AESKULISA (AESKU	ELISA	AESKU	IgG	S1	180
	Enzyme Linked					
	Immunosorbent Assay)					

342			
343			
344			
345			

346

347

Table 2: Results of all six commercial serological assays.

Assay	Positive	Negative	Total	
Test A	52	73	125	
Test B	43	61	104	
Test C	67	37	104	
Test D	50	53	103	
Test E	76	20	96	
Test F	61	38	99	

349

350 Table 3: Performance indicators of the serological assays compared to PRNT

Assay	Sensitivity	Specificity	PPV	NPV	Overall
	(95% CI)	(95% CI)	(95% CI)	(95% CI)	agreement
					with PRNT
					results (95% CI)
Test	71.07	94.64	94.23	72.60	81.6

А	(58.8–81.3)	(85.1-98.8)	(84.1-98.8)	(60.9-82.4)	(73.7-87.9)
Test	75.47	94.12	93.02	78.69	84.61
В	(61.7-86.2)	(83.8-98.8)	(80.9-98.5)	(66.3-88.1)	(76.2-90.9)
Test	98.11	70.59	77.61	97.30	84.62
С	(89.9-99.9)	(56.1-82.5)	(65.8-86.9)	(85.8-99.9)	(76.22-90.94)
Test	84.91	90	90	84.91	87.37
D	(72.4-93.2)	(78.1-96.6)	(78.1-96.6)	(72.4-93.2)	(79.4-93.1)
Test	100	41.67	63.16	100	70.83
Е	(92.6-100)	(27.6-56.7)	(51.3-73.9)	(83.1-100)	(60.7-79.7)
Test	92.31	72.34	78.69	89.47	82.82
F	(81.5-97.9)	(57.4-84.4)	(66.3-88.1)	(75.2-97.1)	(73.9-89.7)

351

Table 4: Test A in parallel testing with other serological tests

Parallel testing		Sensitivity	Specificity
Test A	Test B	92.86	89.07
	Test C	99.46	66.80
	Test D	95.63	85.17
	Test E	100	39.72
	Test F	97.77	68.46

353

Table 5: Test A in serial testing with other serological tests

Serial testing		Sensitivity	Specificity
Test A	Test B	53.53	99.69

Test C	69.65	98.41
Test D	60.27	99.46
Test E	71.0	96.9
Test F	65.54	98.52

355

356

357 Table 6: Area under the curve (AUC) for the serological assays

358

Antibody tests	AUC	95% Confidence Interval
Test A	0.939	(0.888 - 0.990)
Test B	0.935	(0.885 – 0.986)
Test C	0.860	(0.784 -0.936)
Test D	0.953	(0.912 - 0.994)
Test E	0.839	(0.751 - 0.927)
Test F	0.928	(0.871 - 0.984)

359

Table 7: Optimum cut-offs based on the ROC curves and their performances.

361

	Cut offs	Sensitivity	Specificity	Overall agreement
				with PRNT results
Test A	Manufacturer's cut off – 30%	71.0	94.23	81.6
	Based on ROC cut off – 20%	92.31	87.5	90.4
Test C	Manufacturer's cut off - 50	98.11	70.59	84.62

	Based on ROC cut off - 150	83.01	88.23	85.57
Test D	Manufacturer's cut off - 33.8	84.91	90	87.37
	Based on ROC cut off - 40	84.90	96.0	90.29
Test E	Manufacturer's cut off - 0.8	100	41.67	70.83
	Based on ROC cut off - 5	93.75	70.83	82.29

^{*} Tests B and F showed ROC based cut offs similar to the manufacturer's values.

363

364

Figure 1: Serial testing of test C with test A and test B



367

Figure 2: Serial testing of test E with test A and test B



Figure 3: ROC curves for the serological assays







Figure 5: Comparison of the test A performance based on two different cut-off values







386

387